Hu Y, Chen HJ, Ma JH. Individualized intensive insulin therapy of diabetes: Not only the goal, but also the time. World J Diabetes 2024; 15(1): 11-14 [PMID: 38313848 DOI: 10.4239/wjd.v15.i1.11]
Corresponding Author of This Article
Jian-Hua Ma, MD, Professor, Department of Endocrinology, Nanjing First Hospital, No. 32 Gongqingtuan Road, Nanjing 210000, Jiangsu Province, China. majianhua@china.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jan 15, 2024; 15(1): 11-14 Published online Jan 15, 2024. doi: 10.4239/wjd.v15.i1.11
Individualized intensive insulin therapy of diabetes: Not only the goal, but also the time
Yun Hu, Hong-Jing Chen, Jian-Hua Ma
Yun Hu, Hong-Jing Chen, Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu Province, China
Jian-Hua Ma, Department of Endocrinology, Nanjing First Hospital, Nanjing 210000, Jiangsu Province, China
Author contributions: Hu Y and Chen HJ drafted the initial manuscript; Ma JH conceptualized and revised the manuscript.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Hua Ma, MD, Professor, Department of Endocrinology, Nanjing First Hospital, No. 32 Gongqingtuan Road, Nanjing 210000, Jiangsu Province, China. majianhua@china.com
Received: October 27, 2023 Peer-review started: October 27, 2023 First decision: November 23, 2023 Revised: December 3, 2023 Accepted: December 25, 2023 Article in press: December 25, 2023 Published online: January 15, 2024
Abstract
Intensive insulin therapy has been extensively used to control blood glucose levels because of its ability to reduce the risk of chronic complications of diabetes. According to current guidelines, intensive glycemic control requires individualized glucose goals rather than as low as possible. During intensive therapy, rapid blood glucose reduction can aggravate microvascular and macrovascular complications, and prolonged overuse of insulin can lead to treatment-induced neuropathy and retinopathy, hypoglycemia, obesity, lipodystrophy, and insulin antibody syndrome. Therefore, we need to develop individualized hypoglycemic plans for patients with diabetes, including the time required for blood glucose normalization and the duration of intensive insulin therapy, which deserves further study.
Core Tip: Intensive insulin therapy is popular in the treatment of patients with diabetes. This article highlighted the effects and side effects of intensive insulin therapy. It is a warning against the use of insulin therapy without any limitations, such as the speed of blood glucose lowering and the duration of insulin therapy.
